Latest News View More>>
Study finds a common assortment of reasons for non-initiation of HCV therapy, regardless of patient race or ethnicity.
Managing the risk of hepatitis C and liver disease among infants born to mothers with chronic HCV is a challenge.
HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.
Anti-retroviral drug therapy may effectively treat hepatitis C-HIV coinfection.
Antiviral therapies are changing the clinical landscape for the treatment of HCV in developed countries.
Patient access to curative hepatitis C medications remains a challenge.
Study predicts when an HCV cure was achieved and predicts when therapy should be discontinued.
In the US, the incidence of liver cancer rose an average of 2.3% each year overall from 2008 to 2012.
Next generation sequencing reveals frequent opportunities for exposure to hepatitis C virus in Africa.
Coffee appears to confer a number of protective effects against liver disease.
Michael Sofia, PhD, the inventor of the groundbreaking hepatitis C drug Sovaldi, discusses the research that led to the discovery of the groundbreaking HCV treatment.
In part six, Jim Wilson, RPh, MBA, president of WilsonRx, discusses how hepatitis C impacts the entire body.
New hepatitis C drugs moved the dream of a cure into a reality that gives patients a new chance at life.
Journals View More>>
Gaining approval from insurance companies for highly effective new hepatitis C virus treatments is fraught with challenges for patients.
Patients need to take ownership of their treatment regimen.
For hepatitis C virus patients coinfected with HIV, the everyday challenges of managing their condition are amplified.
Long-term damage from the hepatitis C virus is avoidable if you are proactive in seeking help.
Patients need to take ownership of their fight with hepatitis C.